Amneal Takes Control Of AvKARE In US
Offers Access To Departments Of Defense And Veterans Affairs
Amneal has acquired a majority stake in manufacturer and wholesaler AvKARE, giving the firm access to the “large, complex and growing federal healthcare market.”
You may also be interested in...
As Amneal’s generics segment sees significant growth, the company has revealed plans to launch new products and expand in new markets. “We are extremely proud of the progress our company has made since we re-joined as leaders of Amneal,” said Chirag and Chintu Patel, co-CEOs of Amneal.
After launching several high-value complex generic products in the last six months, Amneal aims to launch eight more complex generics by August 2021 to add “tremendous value” to its generics business.
Based on its “solid track record of filing, getting approval and launching high-value generics,” Amneal not only plans to launch eight new “high value” products over the next year, the company also plans to file for another 20-25 generics. Amneal has 91 products in the pipeline awaiting FDA approval and 132 products actively in development, mainly in non-oral solid dosage forms.